{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:25:50Z","timestamp":1788967550985,"version":"build-2803163510"},"reference-count":41,"publisher":"Microbiology Society","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,1]]},"abstract":"<jats:p>\n                  <jats:bold>P<\/jats:bold>\n                  <jats:bold>urpose<\/jats:bold>\n                  <jats:bold>.<\/jats:bold> Antimicrobial resistance (AMR) is of increasing global concern, threatening to undermine recent progress in reducing child and neonatal mortality. Repurposing older antimicrobials is a prominent strategy to combat multidrug-resistant sepsis. A potential agent is fosfomycin, however, there is scarce data regarding its <jats:italic>in vitro<\/jats:italic> activity and pharmacokinetics in the paediatric population.<\/jats:p>\n               <jats:p>\n                  <jats:bold>M<\/jats:bold>\n                  <jats:bold>ethodology<\/jats:bold>\n                  <jats:bold>.<\/jats:bold> We analysed a contemporary, systematically collected archive of community-acquired (CA) and hospital-acquired (HA) paediatric Gram-negative bacteraemia isolates for their susceptibility to fosfomcyin. MICs were determined using agar serial dilution methods and validated by disk diffusion testing where breakpoints are available. Disk diffusion antimicrobial susceptibility testing was also conducted for current empirical therapies (ampicillin, gentamicin, ceftriaxone) and amikacin (proposed in the literature as a new combination empirical therapeutic option).<\/jats:p>\n               <jats:p>\n                  <jats:bold>R<\/jats:bold>\n                  <jats:bold>esults<\/jats:bold>\n                  <jats:bold>.<\/jats:bold> Fosfomycin was highly active against invasive Gram-negative isolates, including 90 \u200a% (202\/224) of \n<jats:named-content content-type=\"family\">\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/doi.org\/10.1601\/nm.3091\" xlink:type=\"simple\">Enterobacteriaceae<\/jats:ext-link>\n                  <\/jats:named-content>\n and 96 \u200a% (22\/23) of <jats:italic>\n                     <jats:named-content content-type=\"genus\">\n                        <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/doi.org\/10.1601\/nm.2552\" xlink:type=\"simple\">Pseudomonas<\/jats:ext-link>\n                     <\/jats:named-content>\n                  <\/jats:italic> spp. Fosfomycin showed high sensitivity against both CA isolates (94 %, 142\/151) and HA isolates (81 %, 78\/96; <jats:italic>P<\/jats:italic> =0.0015). CA isolates were significantly more likely to be susceptible to fosfomycin than the current first-line empirical therapy (96\u200a % vs 59 \u200a%, <jats:italic>P<\/jats:italic> &lt;0.0001). Extended spectrum <jats:italic>\u03b2<\/jats:italic>-lactamases (ESBL) production was detected in 34 \u200a% (85\/247) of isolates with no significant difference in fosfomycin susceptibility between ESBL-positive or -negative isolates [73\/85 (86\u200a %) vs 147\/162 (91 \u200a%) respectively, <jats:italic>P<\/jats:italic> =0.245]. All isolates were susceptible to a fosfomycin-amikacin combination.<\/jats:p>\n               <jats:p>\n                  <jats:bold>C<\/jats:bold>\n                  <jats:bold>onclusion<\/jats:bold>\n                  <jats:bold>.<\/jats:bold> Gram-negative paediatric bacteraemia isolates are highly susceptible to fosfomycin, which could be combined with aminoglycosides as a new, carbapenem-sparing regimen to achieve excellent coverage to treat antimicrobial-resistant neonatal and paediatric sepsis.<\/jats:p>","DOI":"10.1099\/jmm.0.000973","type":"journal-article","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T16:00:34Z","timestamp":1555516834000},"page":"711-719","source":"Crossref","is-referenced-by-count":16,"title":["The potential of fosfomycin for multi-drug resistant sepsis: an analysis of in vitro activity against invasive paediatric Gram-negative bacteria"],"prefix":"10.1099","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2250-0594","authenticated-orcid":false,"given":"Phoebe C. M.","family":"Williams","sequence":"first","affiliation":[{"name":"The University of Oxford, Nuffield Department of Clinical Medicine, Headington, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Waichungo","sequence":"additional","affiliation":[{"name":"KEMRI-Wellcome Trust Research Programme, Kilifi 80108, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Claire","family":"Gordon","sequence":"additional","affiliation":[{"name":"KEMRI-Wellcome Trust Research Programme, Kilifi 80108, Kenya"},{"name":"London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Sharland","sequence":"additional","affiliation":[{"name":"St. Georges University Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Murunga","sequence":"additional","affiliation":[{"name":"KEMRI-Wellcome Trust Research Programme, Kilifi 80108, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Kamau","sequence":"additional","affiliation":[{"name":"KEMRI-Wellcome Trust Research Programme, Kilifi 80108, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Berkley","sequence":"additional","affiliation":[{"name":"The University of Oxford, Nuffield Department of Clinical Medicine, Headington, Oxford, UK"},{"name":"KEMRI-Wellcome Trust Research Programme, Kilifi 80108, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"345","reference":[{"key":"R1","article-title":"Antimicrobial resistance among children in sub-Saharan Africa","author":"Williams","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"R2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0140-6736(15)00474-2","article-title":"Access to effective antimicrobials: a worldwide challenge","volume":"387","author":"Laxminarayan","year":"2016","journal-title":"Lancet"},{"key":"R3","volume-title":"Pocket Book of Hospital Care for Children: Guidelines for the Management of Common Illnesses with Limited Resources","year":"2013"},{"key":"R4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/archdischild-2012-302033","article-title":"Community-acquired neonatal and infant sepsis in developing countries: efficacy of WHO\u2019s currently recommended antibiotics- systematic review and meta-analysis","volume":"98","author":"Downie","year":"2013","journal-title":"Arch Dis Childhood"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piu014"},{"key":"R6","first-page":"9","article-title":"Limiting and controlling carbapenem-resistant Klebsiella pneumoniae","volume":"7","author":"Saidel-Odes","year":"2014","journal-title":"Infect Drug Resist"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30489-9"},{"key":"R8","doi-asserted-by":"crossref","first-page":"e1066","DOI":"10.1016\/S2214-109X(17)30362-5","article-title":"Tackling antimicrobial resistance in neonatal sepsis","volume":"5","author":"Folgori","year":"2017","journal-title":"Lancet Glob Heal"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1126\/science.166.3901.122"},{"key":"R10","volume-title":"Critically important antimicrobials for human medicine","year":"2011"},{"key":"R11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/cid\/cir838","article-title":"Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia","volume":"54","author":"Pulcini","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.12.005"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp282"},{"key":"R14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1469-0691.2011.03636.x","article-title":"Fosfomycin: an old\u2014new antibiotic","volume":"18","author":"Raz","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"R15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/jac\/43.2.211","article-title":"In-vitro activity of fosfomycin against vancomycin-resistant enterococci","volume":"43","author":"Allerberger","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.10.019"},{"key":"R17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijantimicag.2009.03.009","article-title":"Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies","volume":"34","author":"Falagas","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02099-12"},{"key":"R19","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ijantimicag.2015.02.003","article-title":"Susceptibility of anaerobes to fusidic acid and fosfomycin","volume":"45","author":"Boyanova","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.10.2728-2732.2000"},{"key":"R21","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/BF01647220","article-title":"Penetration of fosfomycin into cerebrospinal fluid across non-inflamed and inflamed meninges","volume":"15","author":"Kuhnen","year":"1987","journal-title":"Infection"},{"key":"R22","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/jac\/dkp261","article-title":"Cerebrospinal fluid impairs antimicrobial activity of fosfomycin in vitro","volume":"64","author":"Sauermann","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ijantimicag.2016.02.001","article-title":"Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature","volume":"47","author":"Vardakas","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01852.x"},{"key":"R25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa040275","article-title":"Bacteraemia among children admitted to a rural hospital in Kenya","volume":"352","author":"Berkley","year":"2005","journal-title":"New Engl J Med"},{"key":"R26","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing","year":"2017"},{"key":"R27","volume-title":"Performance Standards for Antimicrobial Disk Susceptibility Tests: Approved Standard","year":"2015"},{"key":"R28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF02013457","article-title":"Factors influencing the activity of the trometamol salt of fosfomycin","volume":"5","author":"Greenwood","year":"1986","journal-title":"Eur J Clin Microbiol"},{"key":"R29","article-title":"Fosfomycin: rationale for the EUCAST clinical breakpoints, version 1.0","year":"2013"},{"key":"R30","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1093\/jac\/dkv221","article-title":"In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa","volume":"70","author":"Walsh","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"R31","article-title":"Breakpoint tables for interpretation of MICs and zone diameters, version 2.0","year":"2012"},{"key":"R32","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1128\/AAC.01834-09","article-title":"Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes","volume":"54","author":"Wachino","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000339"},{"key":"R34","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/21505594.2017.1292196","article-title":"Therapeutic options for carbapenem-resistant Enterobacteriaceae infections","volume":"8","author":"Trecarichi","year":"2017","journal-title":"Virulence"},{"key":"R35","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofv050","article-title":"Treatment options for carbapenem-resistant Enterobacteriaceae infections","volume":"2","author":"Morrill","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01235-09"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.01.010"},{"key":"R38","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1086\/527442","article-title":"Fosfomycin: use beyond urinary tract and gastrointestinal infections","volume":"46","author":"Falagas","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr466"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.08.010"},{"key":"R41","article-title":"Breakpoint tables for interpretation of MICs and zone diameters"}],"container-title":["Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.000973?crawler=true&mimetype=application\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T19:24:36Z","timestamp":1702668276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.000973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1099\/jmm.0.000973","relation":{},"ISSN":["0022-2615","1473-5644"],"issn-type":[{"value":"0022-2615","type":"print"},{"value":"1473-5644","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,1]]}}}